Jefferies Financial Group Initiates Coverage on Urogen Pharma (NASDAQ:URGN)

Key Points

• Jefferies initiated coverage on Urogen Pharma (NASDAQ:URGN) with a Buy rating and a $40 price target, implying roughly a 94.8% upside
• Shares opened at $20.53 (market cap ~$999M); UroGen reported Q results with EPS of -$0.54 beating estimates but revenue of $37.84M missing expectations, and the 12‑month range is $3.42–$30.00.
• Insiders sold stock in early February, trimming their positions, while institutional ownership remains very high at 91.29%, signaling strong institutional accumulation despite insider exits.

Equities researchers at Jefferies Financial Group assumed coverage on shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) in a note issued to investors on Friday. The firm set a "buy" rating and a $40.00 price target on the stock. Jefferies Financial Group's target price points to a potential upside of 94.84% from the company's current price.

Several other analysts have also issued reports on URGN. Weiss Ratings reiterated a "sell (d-)" rating on shares of Urogen Pharma in a report on Wednesday, January 21st. Oppenheimer restated an "outperform" rating on shares of Urogen Pharma in a research note on Monday, March 2nd. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Urogen Pharma has an average rating of "Moderate Buy" and an average target price of $34.13.

Urogen Pharma Stock Performance

Urogen Pharma stock opened at $20.53 on Friday. The firm has a market cap of $999.40 million, a PE ratio of -6.42 and a beta of 1.43. The firm's 50 day moving average price is $19.59 and its two-hundred day moving average price is $20.75. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $30.00.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.12. The company had revenue of $37.84 million for the quarter, compared to analyst estimates of $39.92 million. Equities analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the completion of the sale, the insider owned 144,985 shares of the company's stock, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,479 shares of the company's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the sale, the general counsel owned 51,326 shares of the company's stock, valued at $1,010,608.94. This represents a 12.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.70% of the stock is currently owned by company insiders.

Institutional Trading of Urogen Pharma

Several large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its holdings in Urogen Pharma by 36.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 534,545 shares of the company's stock worth $10,664,000 after purchasing an additional 144,181 shares during the last quarter. Squarepoint Ops LLC boosted its position in Urogen Pharma by 187.8% during the second quarter. Squarepoint Ops LLC now owns 94,309 shares of the company's stock worth $1,292,000 after purchasing an additional 61,545 shares during the period. GSA Capital Partners LLP acquired a new position in Urogen Pharma during the third quarter valued at approximately $977,000. NEOS Investment Management LLC acquired a new position in Urogen Pharma during the third quarter valued at approximately $1,007,000. Finally, Privium Fund Management B.V. raised its position in shares of Urogen Pharma by 82.7% in the third quarter. Privium Fund Management B.V. now owns 196,622 shares of the company's stock valued at $3,923,000 after purchasing an additional 89,000 shares during the period. Institutional investors own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.